mTOR
Cell signaling | Growth • Metabolism • Aging Biology
Common names: mTOR · mTORC1 · mTORC2 · mechanistic target of rapamycin · rapamycin pathway
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
mTOR is one of the systems cells use to decide when to grow, build and conserve resources. In animals, dialing down this pathway with drugs like rapamycin can extend lifespan. That is why longevity circles pay so much attention to it. Human studies are much less definitive and do not show that rapamycin extends lifespan or broadly reverses aging in healthy people.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying mTOR across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Current stage not published
- Selected source context
- Human · Mixed · Research Review
At a Glance
Research snapshot.
- 01Research Base
Extensive molecular and model evidence - 02Human Research
Smaller geroscience literature - 03Key Distinction
Pathway biology ≠ therapy proof - 04Human Lifespan
Not established
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
mTORC1 integrates nutrient, growth-factor, and cellular-energy signals to regulate anabolic and catabolic processes.
- Evidence bucket
- lab mechanistic
- Research stage
- foundational
- Route / format
- mTORC1 pathway biology
Explore the evidence
lab/mechanistic
mTORC1, the maestro of cell metabolism and growth.
lab/mechanistic
Nutrient sensing of mTORC1 in cancer and aging.
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
4V Take
mTORC1 signaling is closely involved in protein synthesis, metabolism, and autophagy regulation.
- Evidence bucket
- lab mechanistic
- Research stage
- foundational
- Route / format
- mTORC1 pathway biology
Explore the evidence
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
4V Take
Rapamycin extends lifespan in multiple model organisms, but human lifespan extension has not been established.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- model-organism longevity and human translation
Explore the evidence
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
4V Take
Human trials of low-dose mTOR inhibition have shown selected immune-function and infection-related signals in older adults.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- low-dose mTOR inhibition in older adults
Explore the evidence
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
4V Take
A 2024 systematic review found human effects to be system-specific rather than evidence of broad aging reversal.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- human rapamycin and derivative studies
Explore the evidence
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
4V Take
Current human evidence does not establish off-label rapamycin as a proven longevity treatment for healthy adults.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- off-label rapamycin in healthy adults
Explore the evidence
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
TORC1 inhibition enhances immune function and reduces infections in elderly.
Not specified in evidence brief · PMID: 29997249 · peer reviewed
human synthesis
Targeting ageing with rapamycin and derivatives in humans: systematic review.
2024 · PMID: 38310895 · peer reviewed
human synthesis
Clinical evidence for off-label rapamycin in healthy adults.
Not specified in evidence brief · PMID: 40778880 · peer reviewed
lab/mechanistic
mTORC1, the maestro of cell metabolism and growth.
Not specified in evidence brief · PMID: 39572234 · peer reviewed
lab/mechanistic
Nutrient sensing of mTORC1 in cancer and aging.
Not specified in evidence brief · PMID: 39153724 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Related Research
Continue with context.
Connections are limited to approved topic context. Each linked topic keeps its own evidence boundaries and Research Stage.
AMPK
Pathway contextThese pathway topics are useful to read together while keeping each page’s approved limits and outcome questions distinct.
Research Stage: Foundational
Foundational biology is not proof of a longevity intervention.
Autophagy
Related pathwayBoth pages address cellular pathway context and retain distinct limits on translating biology into outcomes.
Research Stage: Foundational / Developing
Research stages and evidence boundaries remain topic-specific.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.